RT Journal Article
SR Electronic
T1 PS2:41 Microrna-155 and disease activity in sle patients
JF Lupus Science & Medicine
JO Lupus Sci & Med
FD Lupus Foundation of America
SP A52
OP A53
DO 10.1136/lupus-2018-abstract.89
VO 5
IS Suppl 1
A1 Shumnalieva, R
A1 Kachakova, D
A1 Shoumnalieva-Ivanova, V
A1 Miteva, P
A1 Monova, D
A1 Kaneva, R
A1 Monov, S
A1 Popova, V
YR 2018
UL http://lupus.bmj.com/content/5/Suppl_1/A52.2.abstract
AB Background Recent studies are trying to identify aberrant microRNA levels as a diagnostic signature of SLE as well as to understand the role of specific microRNAs as biomarkers for disease activity (DA) and progression. Our aim was to evaluate the peripheral blood (PB) expression of miR-155 in SLE patients and to determine its correlation with the DA in the clinical practice.Materials and methods We studied 40 SLE patients and 32 healthy controls. miR-155 expression levels in whole PB samples were determined by PCR (SYBR Green technology). 2-δδCt method was used for analysis. The DA was assessed by SLE DA index (SLEDAI).Results miR-155 was upregulated in 50.0% of the patients and without difference in its expression levels in 17 (42.5%) of the patients. ROC curve analysis was conducted in order to evaluate the diagnostic accuracy of the PB expression levels of the studied miRNA. AUC for miR-155 was 0.691 (95% CI: 0.566 to 0.817), p=0.005 with 77.5% sensitivity and 50.0% specificity when the RQ cut value was 1.03. Levels of miR-155 correlated with the diagnosis (rs 0,330, p=0,005), with patient’s age (rs 0,366, p=0,002) as well as with the presence of secondary Raynaud phenomenon (rs 0,250, p=0,035). There was no correlations with SLEDAI (p=0, 894) nor with the immunological activity according to ANA titer (p=0.399), a-dsDNA (p=0.817), a-Sm (p=0.285), a-b2GPI (p=0.903), a-CL antibodies (p=0.857) and C3 and C4 complement levels (p=0.062 and p=0.550, respectively).Conclusions We found a dysregulation of miR-155 in SLE which could suggests its role in the disease pathogenesis. There was no correlation between PB levels of miR-155 and DA as a whole as well as with the immunological activity which might reflect the variants of SLE DA in the studied patients, the difference in their genetic background or in the used medications but larger study is needed to confirm these results in the clinical practice.Acknowledgement The study was supported by Grant 53/2014 funded by Medical University Sofia, Bulgaria.